Skip to main content

Topotecan

Chronic CED of TPT for Recurrent Malignant Glioma

  • RegistryNCT06666712
  • PhasePhase 1
  • StatusRecruiting
  • ConditionBrain Tumor, Recurrent
  • SponsorJeffrey N. Bruce
How TPT CED rHGG worksNCT066667124 min

What the film says

Read the transcript

Some brain tumors announce themselves fast. Others take their time. An IDH-mutant glioma is the patient one.

It begins with a typo. IDH is an enzyme in the cell's energy cycle, and in more than seven out of ten lower-grade gliomas, one letter of its gene is wrong. The altered enzyme makes a chemical the body has no use for, and that chemical jams the machinery a cell uses to read its own genes. The tumor that follows grows slowly. It tends to arrive in people in their thirties. And after surgery, radiation and chemotherapy, it comes back. Nearly always, and often more aggressive than before.

When it does come back, there is no standard treatment.

Here is the frustrating part. Drugs that kill these cells in a dish already exist. Topotecan is one. Given by vein, it failed completely in recurrent glioblastoma: in one study, none of twenty-eight patients responded. The drug was not the problem. Getting it to the tumor was.

The brain protects itself. Blood vessels in the brain are sealed shut with tight junctions, and pumps in their walls push foreign molecules back out. It is a good wall, and it cannot tell a poison from a treatment. Raise the dose in the bloodstream enough to force the wall and you poison the rest of the body first.

So what if you skipped the bloodstream?

That is convection-enhanced delivery. A surgeon places a fine catheter into the tumor and the brain around it, and a pump pushes the drug in under gentle pressure. Not diffusion, which fades within millimeters, but bulk flow, which carries a drug centimeters through tissue. Add a contrast agent to the mix and an MRI scan will show you exactly where the drug went.

One more detail shapes the whole design. Topotecan only kills a cell that is actively copying its DNA, and at any moment only a few tumor cells are. A short infusion misses the rest. But the early versions of this ran a tube out through the scalp to a pump at the bedside, and after about four days the risk of infection ends the treatment.

The fix was to put the pump inside the body. A programmable pump, the kind already implanted to deliver pain medicine to the spine, sits under the skin of the chest, is refilled through a needle, and can run as long as it is needed.

In twenty twenty-two, a team at Columbia published the first five patients treated this way. Four infusions of forty-eight hours each, over about a month, with patients at home in between. No severe side effects were blamed on the drug. When the treated tissue was examined afterwards, the share of dividing tumor cells had fallen from roughly four percent to one and a half, and the drug was found as far as six centimeters from the catheter. All five patients eventually died of their disease, and the authors were careful to say that five patients cannot prove benefit.

That study treated a different subtype. This trial brings the method to IDH-mutant tumors for the first time. Six adults whose glioma has returned, at Columbia University in New York, led by Jeffrey Bruce, who has spent a career on this problem. Two operations, four infusions, and one question first. Is it safe?

Everything in this film comes from the published record, and it is not medical advice.

Sources behind this film

Show 8 more sources

The drug

What is being tested.

Topotecan (TPT) is a chemotherapeutic agent that is a topoisomerase inhibitor. This intervention is uniquely distinguished through its administration using an externalized catheter and external microinfusion pump (Convection-Enhanced Delivery)

Malignant gliomas are among the most pernicious of human tumors. They are locally invasive and universally recurrent, often recurring within two centimeters of the original resection cavity.

Although numerous chemotherapeutic drugs demonstrate significant anti-tumor activity in preclinical studies, their efficacy in clinical trials has been dismal; systemic delivery fails to achieve therapeutic drug levels in tumor cells due to various factors including limited blood-brain barrier permeability and systemic toxicity.

The study

How the trial runs.

The primary goal of this study is to establish the safety of chronic Convection Enhanced Delivery (CED) of the chemotherapeutic drug Topotecan for patients with recurrent malignant glioma that harbors the Isocitrate Dehydrogenase mutation (IDH-mut). The secondary goal of the study is to study drug distribution and assess the tumor response to prolonged continuous CED of Topotecan.

Convection Enhanced Delivery is a novel method of drug delivery that allows administration of a drug directly to the brain. In CED, a drug pump is placed under the skin in the chest or abdominal region. The pump is connected to a catheter that is tunneled underneath the skin to the brain. The tip of the catheter then infuses Topotecan directly onto the brain tumor.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Patients must have recurrent malignant glioma with a history of WHO grade 3-4 IDH-mutant status and evidence of radiographic progression and suspicion of histopathological recurrence. Stereotactic biopsies will be performed to assess the presence of active tumor by frozen section prior to initiating treatment. Patients with a history of WHO grade 2 recurrent glioma, IDH-Mutant, who now demonstrate high-grade features of IDH-mutant WHO grade 3-4 will also be included.
  • Patients with recurrent malignant glioma, IDH-mutant, who have failed standard of care treatment are eligible.
  • An MRI scan must be obtained within 30 days of enrollment and must demonstrate an enhancing mass without significant mass effect. Tumors must be less than 32 cc in total volume as assessed by the principal investigator based on pre-enrollment MRI. The lesion must be stereotactically accessible.
  • Karnofsky performance score must be greater than or equal to 70.
  • Men and women of childbearing potential must practice birth control. Women of childbearing potential must have a urine pregnancy test within 7 days of study entry. In accordance with topotecan administration guidelines, women must practice birth control for at least 1 month following chemotherapy infusion. Men must practice birth control for at least four months following termination of chemotherapy infusion.
  • Patients or appropriate legally authorized representatives must possess the ability to give Informed Consent.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.